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ABSTRACT
Background:  Eosinophilic  Esophagitis  (EoE)  is  a  Th2  mediated  disease 
characterized by patchy eosinophilic esophageal infiltration. In other Th2 mediated 
diseases  such  as  Atopic  Dermatitis  (AD),  there  is  a  significantly  reduced 
expression of the  antimicrobial peptides and proteins (AMPs),  a family of small  
cationic peptides that protect their hosts against infectious microorganisms. AMPs 
have never been characterized before in EoE. In the present work we hypothesize 
that similarly to AD AMPS may be dysregulated in EoE.  
Aim: We  investigated the presence and expression levels of selected AMPs in 
esophageal biopsies of children with active EoE (n=5), with EoE in remission (n=5) 
and in healthy controls (n=5). 
Methods: Biopsies were analyzed by Real-Time quantitative PCR (RT-qPCR) for 
human Beta-Defensin-(hBD) 1 and 2,  cathelicidin,  elafin and psoriasin and by 
immunohistochemestry  hBD1,  elafin  and  psoriasin.   Statistical  analysis  was 
performed using  Kruskall-Wallis test or  One-Way ANOVA followed by Bonferroni 
post-hoc test. Values of P<0.05 were considered statistically significant. 
Results: Table 1 summarizes principal findings. 
AMP RealTime qPCR IHC
Active EoE Not Active 
EoE
Active EoE Not Active 
EoE
Active + Not 
Active EoE
hBD1 ⬆ vs control
(1.87 ± 3.56)
⬇ vs control
(0.54 ± 0.54)
⬇vs active ✵ N/A
hBD2 ⬇ vs control
(0.15 ± 0.14)
⬇ vs control
(0.22 ± 0.14)
N/A N/A N/A
Cathelici­
din
 =vs control
(1.19 ± 1.12)
 =vs control
(1.32 ± 1.45)
N/A N/A N/A
Elafin ⬇ vs control
(0.41± 0.38)
⬇ vs control
(0.52 ± 0.42)
⬇ vs control ⬇ vs control ⬇vs control ✵
Psoriasin  =vs control
(1.87 ± 2.14)
 =vs control
(1.45 ± 2.16)
⬇vs control ✵ ⬇vs control ✵ ⬇vs control ✵
Table 1: summary of presented data. Red boxes indicate upregulation, green boxes indicate down­
regulation. Numbers between parenthesis indicate fold expression.  ✵  indicate statistically signifi­
cant data, p<0.05. N/A not assessed
Conclusions: Although this is a small population, we were able to demonstrate 
that a possible dysregulation of AMPs expression is present in children with EoE. 
Larger studies will be required to confirm the above findings.
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BACKGROUND
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Eosinophilic esophagitis
Definition
In the last decades it has been observed an increase of patients with esophageal 
eosinophilia, who were initially thought to be affected by gastro-esophageal refux 
disease (GERD). Due to the poor response to common therapies for GERD, such 
as protonic pomp inhibitors, a new disease was delineated, subsequently known 
as Eosinophilic Esophagitis (EoE).
EoE, as defined during the First International Gastrointestinal Eosinophil Research 
Symposium in 2007, is a “a clinico-pathologic condition characterized by oesopha­
geal symptoms and a dense oesophageal eosinophilia, both of which persist des­
pite prolonged treatment with proton pump inhibitors, whereas eosinophilic infam­
mation is absent in the other sections of the digestive tract” [1]. However, very re­
cently, a new conceptual definition of EoE has been delineated by a task force of 
33 physicians with recognized expertise on this disease. A number of recent basic, 
translational and clinical studies have, indeed, highlighted the increasing role of 
genetics and the existence of different phenotypes of EoE, rather defining a “spec­
trum” than a single disease. In this way, EoE should be defined as “a chronic, im­
mune/antigen-mediated esophageal disease characterized clinically by symptoms  
related to esophageal dysfunction and histologically by eosinophil-predominant in­
flammation.” [2].
Epidemiology
EoE has been reported from every part of the world except Africa, an observation 
that may be consistent with the hygiene hypothesis of allergic diseaseʼs distribu­
tion.  It  seems  to  be  more  predominant  in  men and  in  white  population  [3-5], 
clusters into families and it is associated with allergic sensitization [6] and other 
atopic diseases [7, 8].
In the last decade an increase in the incidence of EoE has been noted, and, ac­
cording to different epidemiological studies, the prevalence of this disease seems 
to be comparable to that of infammatory bowel diseases but less than celiac dis­
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ease [9, 10]. Over a 16-year observation period, between 1989 and 2004, Strau­
mann et al found an increasing prevalence from 2 to 23 per 100,000 persons in a 
Swiss population that included children and adults [11]. A population based study 
from the United States reported an increasing incidence from 0.35 to 9.45 per 
100,000  persons  from  1991-1995  to  2001-2005  [12].  Another  study  from  the 
United States demonstrated a 35- fold increase between 1994 and 2003 [7] and 
an Australian study [13] an 18-fold increase in the prevalence of EoE. However, 
there are some pediatric studies suggesting that the incidence of EoE remains 
stable, at least in pediatric age. From 2000 to 2003, in Hamilton county (Ohio,  
United States), Noel et al [14] reported an annual incidence of EoE of 1 case per 
10,000 in children and a prevalence of 4.3 cases per 10,000. Recently, DeBrosse 
et al [15] did not find any changes in the incidence of pediatric EoE in an observa­
tion period from 1982 to 1999, even after correction for a 40-fold increase in the 
number of performed endoscopies. For these contrasting results, further prospect­
ive and population-based studies, on children and adults, are needed to confirm 
these epidemiological observations.
Pathophysiology
In normal conditions, esophageal mucosa is devoid of eosinophils, which can how­
ever be found in duodenal mucosa and in small intestine; therefore attractants and 
degranulation triggers for eosinophils must play a central role in the pathogenesis 
of EoE. The pathophysiology of EoE is due to multifactorial causes including envir­
onmental and allergic triggers, genetic predisposition and, probably, a defect of the 
innate immune system (figure 1).
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Figure 1: pathophysiology of EoE. APC: antigen presenting cells, ECP: eosinophil cationic protein,
EDN: eosinophil derived neurotoxin, MBP: major basic protein, TGFβ: transforming growth factor β.
(From Shahzad et al. [16])
In fact, recent studies have highlighted that EoE is thought to be a Th2-mediated 
disease, in the context of genetically predisposed individuals and an inciting envir­
onmental trigger [17]. A very interesting review deeply analyzed the possible role 
for immune system cells and cytokines in the pathogenesis of EoE [18]. This re­
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view concludes that “the causative events that lead to EoE in humans remain un­
known”.
Eosinophils are recruited and activated into infammatory sites and are regulated 
by Th2-skewed cytokines such as IL-4, IL-5, IL-13, IL-14 and TNF which are pro­
duced by activated Th2 and mast cells [19]. In EoE, esophageal mast cells and 
Th2 become activated by antigen-presenting cells (APC) processing food or air al­
lergens (figure 2).
Figure 2: APC process and present the allergens to the T cells, which home to the esophagus by 
way of blood circulation and, on activation, release eosinophil-specific cytokines (IL-5 and IL-13),  
which induce chemokines (eotaxin -1, -2, and -3) in the esophageal epithelium that attract eosino­
phils into the esophagus. The activated eosinophil and mast cells are a rich source of TGF-β, which 
may play a critical role in the disease pathogenesis, including esophageal remodeling (from Mishra 
A. [20]).
After their activation, eosinophils degranulate and up-regulate their cytokines pro­
duction. Eosinophils release four major cationic proteins contained in pre-formed 
granules  (eosinophil  peroxidase,  eosinophil  cationic  protein,  eosinophil-derived 
neurotoxin and major basic protein) and produce a wide range of cytokines that 
potentiate the infammatory response (IL-1, IL-3, IL-4, IL-5, IL-6, IL-8, GMCSF, TG­
Fα/β, TNFα and eotaxin). The chronic eosinophilic infammation leads to the de­
position of fibrous tissue in the sub-epithelial layers, a process called ʻesophageal 
remodelingʼ that represents a major long-term sequela of untreated persistent EoE 
[21, 22]. The connective tissue deposition in the sub-epithelial layer may, in the 
long-term, lead to the alteration of the esophageal function and to luminal narrow­
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ing, resulting in some of the typical findings of eosinophilic esophagitis, such as 
strictures and rings, that lead to the typical clinical presentation (figure 3, below).
The role of allergy in the pathogenesis of EoE is suggested by several findings: 
most patients are atopic (food and inhalants sensitization), demonstrate full dis­
ease remission after starting an elemental diet and recrudescence after reintroduc­
tions of food allergens [23, 24], and respond to steroid therapy (as in other atopic 
diseases, as atopic dermatitis and asthma). 
In a large pediatric cohort, one study showed that two-thirds of children with EoE 
had concomitant atopy, of which 231 had asthma (37%), 243 had allergic rhinitis 
(39%) and 78 had atopic dermatitis  (13%) [25].  Other studies have reported a 
higher prevalence of atopy with food and inhalants sensitizations in pediatric or 
adult patients with EoE, higher than the general population [5, 8, 26]. Moreover,  
aero- and food allergens also play a role in the pathogenesis of EoE, as demon­
strated by the model by Seema et Aceves (figure 3) [27].
Figure 3: Potential pathogenesis and effects of tissue remodeling in patients with EoE. Aero and 
Food  allergen  drives  epithelial  infammation  and  production  of  chemokines,  interleukins,  and 
growth factors, causing the remodeling. This remodeling, in turn, causes the abnormalities visible 
on endoscopy and esophageal dysfunction, determining clinical symptoms and further complica­
tions. Topical steroids, biologic agents, and antigen elimination might be able to alter the course to  
remodeling. FGF-9, Fibroblast growth factor 9. (From Seema S. Aceves. [27])
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Genetics
Genetics surely plays an important role in the pathogenesis of EoE, as highlighted 
in a recent review by Brown-Whitehorn and Spergel [28].
EoE shows a strong familial association with nearly 10% of parents of EoE pa­
tients  having  a  history  of  esophageal  strictures  and  about  8% having  biopsy-
proven EoE [29].
Blanchard et al [30] have demonstrated, using a genome-wide microarray, a dys­
regulation of 1% of the expressed genes in patients with EoE compared to healthy 
controls  (Figure  4).  The  highest  up-regulated  gene  was  eotaxin-3,  a  specific 
chemo-attractive cytokine responsible for the accumulation and adhesion of eos­
inophils. The role of eotaxin-3 in EoE pathogenesis is also confirmed by the obser­
vation that eotaxin receptor-deficient mice are protected from experimental EoE.
Figure 4: microarray of mRNA from normal (NL) human esophageal mucosa and from eosinophilic 
esophagitis (EE). Down-regulated genes are shown in blue and up-regulated genes in red (From: 
Blanchard et al [30]).
Rothenberg et al  [31] have reported an association of EoE with variants at chro­
mosome 5q22 encompassing TSLP (thymic stromal lymphopoietin) and WDR36 
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(WD repeat containing protein 36) genes. TSLP is an epithelial-derived cytokine 
that activates professional antigen-presenting cells, such as dendritic cells, which 
initiate Th2-type allergic responses, highlighted in EoE patients [32].  TSLP has 
also been found to be associated with atopic dermatitis [33] and asthma [34] com­
pared with healthy controls.
A recent study by Sherrill et al [35] has showed a significant association between 
specific TSLP variants (found with the genetic analysis of single nucleotide poly­
morphism (SNP) of TSLP and TSLP receptor) and atopic disease. Moreover, res­
ults from this study have suggested a unique potential mechanism for the induc­
tion of EoE. Food allergens can trigger the TLR-3 (toll like receptor) receptor, indu­
cing TSLP and finally causing the activation of the Th2 pathway and subsequently 
leading to the eosinophilic esophageal infammation. However, more studies are 
needed to better understand the genetics of EoE.
Diagnosis
Diagnosing EoE presents some clinical and histological issues.
Clinical symptoms (table 1) complained by patients are not exclusively found in 
this  disease,  and even histological  finding (table  2) are,  sometimes,  non com­
pletely reliable.
Table 1: Clinical picture of EoE. (From: Gupte and Draganov. [36])
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Table 2: Clinical signs in EoE. (From: Gupte and Draganov. [36])
Different guidelines for diagnosis of EoE have been published; although, most of 
them could be summarized in these following (table 3):
Table 3: Diagnostic guidelines for EoE. (From: Schoepfer AM, et al. [37])
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Clinical presentation
In children typical symptoms are: refuse of feeding, food impaction, dysphagia, 
vomiting, abdominal pain and heartburn; some children could also present with 
failure  to  thrive  (Table  1).  Although  these  symptoms  could  suggest  other  dia­
gnoses, such as GERD, and different endoscopic findings have been identified, 
none of them are strictly pathognomonic for EoE. Moreover, although esophageal 
eosinophilia is a primary histologic feature of EoE, this finding could be present in 
other diseases, such as GERD [38], Crohnʼs disease and ulcerative colitis [39], 
drug associated esophagitis, and hypereosinophilic syndrome [40].
Histologic findings
The first records of histologic findings associated with EoE were reported in the 
1970s [41, 42], although one of the most characteristic feature of EoE, circular 
rings, was already reported twenty years before, in 1953 [43]. Histological features 
(figure 5, 6) associated with EoE are: i) at least 15 intraepithelial eosinophils/HPF 
at peak count; ii) presence of eosinophils micro-abscesses iii) superficial layering 
of eosinophils iiii) basal zone hyperplasia. Moreover, due to the high rate of allergic 
diseases in EoE patients, a complete allergy evaluation is recommended.
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Figure 5: Microscopic 
appearance of EoE: biopsy 
specimens have characteristic 
mucosal eosinophilia and 
epithelial proliferation . 
Eosinophils layer on the luminal 
surface and form micro-
abscesses (arrow). Microscopic 
examination would also note 
numerous degranulating 
eosinophils.  (From: Noel  and 
Tipnis [44])
Figure 6: Pictures of esophageal furrowing. (From: Furuta et al. [1])
Differential diagnosis and management of EoE
The  differential  diagnosis  of  EoE,  such  as  GERD,  eosinophilic  gastroenteritis, 
Crohnʼs  disease,  connective  tissue  diseases,  hyper-eosinophilic  syndromes, 
should be ruled out. Treatment usually comprises isolated or a combination of ap­
proaches which include: medical (local and systemic steroids, acid suppression 
drugs, leukotriene receptor antagonists and mast cell stabilizers, biological drugs), 
surgical (esophageal dilatation) and/or dietary (food elimination).
Figure 7: Algorithm for EoE management and treatment. (From: Garrean and Hirano. [45]
The first step ( figure 7) in the treatment of EoE is an empiric 6- to 8- week trial of 
acid suppression therapy, as suggested by the First International Gastrointestinal
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Eosinophilic  Research  Symposium  in  2007.  Due  to  the  possible  concomitant 
GERD, without the acid suppression therapy, endoscopy cannot confirm EoE dia­
gnosis.
Systemic  corticosteroids,  although highly  effective  in  improving  symptoms and 
esophageal histology, should be reserved for patients with severe symptoms. A 
short-term course could be considered when hospitalization is required or in case 
of  development  of  esophageal  stricture.  Topical  swallowed corticosteroids  is  a 
mainstay of EoE treatment in adults and in children, as some studies have already
demonstrated [46-48]. Topical steroids have less side effects than those seen with 
systemic  corticosteroids;  however,  disease  recurrence  generally  occurs  when 
treatment is suspended. 
Anti IL-5 therapy is currently under investigation in two pediatric studies, based on
the efficacy observed in a open-label phase TT study in four adult patients [49]. Al­
though new recent  discoveries  and innovative therapeutical  approaches,  some 
questions still remain unresolved, among them, the understanding of the etiology 
and pathogenesis of EoE which could better address diagnostic tests and treat­
ment choices.
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Antimicrobial peptides and proteins
The human immune system is composed of an innate and an adaptive system, to
protect itself from exogenous and endogenous insults. The innate immune system
has two major components: cells (e.g. leukocytes) and humoral mediators (e.g. cy­
tokines, antimicrobial substances). Antimicrobial substances comprise microbicidal 
chemicals (e.g., hydrogen peroxide, nitric oxide, etc.) and a wide variety of host 
gene-encoded antimicrobial peptides and proteins [50] .
Antimicrobial peptides (AMPs) are a family of small cationic peptides that belongs 
to  the  innate  branch  of  the  immune  system  [51].  These  peptides,  which  are 
present in several species, protect their hosts against infectious microorganisms 
and have a role in the molecular cascade of some infammatory diseases.
Different AMPs have been described in humans, that could be classified upon their
molecular structure into [52, 53]:
1) linear α-helical peptides free of cysteine residues (e.g. human cathelicidin);
2) peptides with a β-sheet globular structure stabilized by 3 intramolecular disulf­
ide bonds (e.g. human defensins);
3) peptides with unusual bias in certain aminoacids, such ad histidine, glycine, pro­
line or tryptophan (e.g. bovine indolicin).
The most  documented and known AMPs are defensins,  although some others 
have been studied,  as cathelicidin  and psoriasin  in  skin  diseases.  AMPs have 
been studied mostly in infammatory bowel diseases (table 4) [54], in skin (table 5) 
and respiratory diseases [55].
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Table 4: AMPs in infammatory bowel diseases (from Jager S et al. [54])
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Table 5: AMPs in the skin (from Wiesner J and Vilcinskas A. [56])
Role and functions of AMPs
Several  reviews have analyzed different  types and roles of  AMPs [53,  57-59].  
AMPs are virtually present in the whole human body, especially in the skin and in 
mucosal epithelia, which are tissues in direct contact with the outside environment.
It has been demonstrated that AMPs have a double role in humans: they have an­
timicrobial  functions  and  act  as  immuno-modulatory  molecules  in  several  dis­
eases,  such  as  infammatory  bowel  diseases  (IBDs),  atherosclerosis,  cystic 
fibrosis and psoriasis (figure 8).
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Figure 8: Functions of AMPs in infammatory diseases. Various cell types are activated by microbes and
infammatory mediators, causing the production and release of AMPs. These peptides show different functions 
including antimicrobial activity and modulation of the infammatory response. However, an imbalance in the
activity of AMPs leads to the development of infectious or infammatory diseases. Abbreviations: AMPs,
antimicrobial peptides; LPS, lipopolysaccharides. (from Guaní-Guerra E et al. [57])
Currently, the exact mechanism of action of each AMPs is not completely known.
Different models (figure 9) have been proposed but it is unknown which of the pos­
sible mechanisms is closest to reality [60].
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Figure 9: Schematic presentation of the three major models explaining how cationic amphipathic
AMPs insert into lipid bilayers or lead to membrane disruption. Hydrophilic and lipophilic parts of  
the AMPs are indicated in light grey and black respectively. (from Wiesner J and Vilcinskas. [56])
For the purpose of this thesis, only a selection of human AMPs will be analyzed in 
depth: beta-defensins (hBD), cathelicidin, elafin and psoriasin.
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HUMAN β-DEFENSINS
The most described and represented human AMPs are defensins, which are char­
acterized by a triple-stranded β-hairpin  structure,  six  conserved disulfide-linked 
cysteine residues and a positive net charge. Based on the cysteine pairing, it is 
possible to divide them in two subfamilies: the alpha(α)-defensins and the beta(β)-
defensins (figure 10).
Figure 10: Structure of α-defensins (A), β-defensins (B) and θ-defensins (C). (from Hazlett L, Wu M. [61])
In humans, six α-defensins have been identified: HNP (human neutrophil peptide) 
-1 to HNP-4 in the azurophilic granules of neutrophils, and HD (human defensin) 
-5 and -6 mainly secreted from the Paneth cells in the small intestine. Several β-
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defensins, too, have been characterized (table 6) and are mainly produced by epi­
thelial cells; hBD (human beta defensin) -1 to -4 are those better known and char­
acterized. All  α-  and the  β-defensins  have broad antimicrobial activities (viruses, 
bacteria, fungi) and some chemoattractant properties. A third class of defensins 
(θ-defensins) have been described, but not in humans.
Table 6: Tissue distribution, cell source, synthesis and regulation of β-defensins. (from  Klotman 
ME, Chang TL. [62])
Genetics and structure
The genes encoding human β-defensins are located on the chromosome 8:
hBD1 (DEFB1) [63]; hBD2 (DEFB4) [64]; hBD3 (DEFB103) [65]; hBD4 (DEFB104) 
[66, 67] ; hBD5-9 (DEFB05-DEFB9) [66, 68-70].
Source and expression
The primary source of hBD1-4 is epithelial cells; however, these β-defensins are 
also expressed in monocytes and macrophages [62]. Whereas the highest levels 
of hBD1-3 were detected in skin, sweat glands, lung, respiratory, and urogenital  
tracts [71-77],  hBD4 and several  recently discovered β-defensins (hBD5-9, hB­
D18-21, hBD23 and hBD25-29) are mainly present in placenta, testis, and epidi­
dymis [66, 67, 69, 70, 78, 79].
While in the primary epithelial cells a basic level of hBD1 is supplied by the con­
stitutive expression with slight modulation during the infammation [72, 74, 80-82], 
expression of hBD2-4 is clearly inducible [80-82]. The synthesis pattern of human 
epithelial defensins 2 through 4 involves multiple, distinct signaling pathways [83]. 
In general, inducible up-regulation of the hBD2-3 expression was observed in re­
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sponse to bacterial and viral infections or such microbial components as lipopro­
teins,  peptidoglycan,  lipopolysaccharides  (LPSs),  lipoteichoic  acid  (LTA),  proin­
fammatory  cytokines  (IL-1α,  IL-1β,  TNF-α),  growth  factors  (TGF-α,  IGFI),  and 
some chemical agents like 1,25-dihydroxyvitamin D3 or phorbol 12-myristate 13-
acetate [65, 67, 71, 80, 82, 84-87].
Functions and role in humans
The first  hBD1 was identified in 1995 and purified from the plasmafiltrates of pa­
tients with renal disease, from haemofiltrates [88], while its mRNA was found to be 
predominantly expressed in epithelia of the urogenital tract [72]. The previously re­
ported genomic hBD-1 sequence does not contain transcription factor regulatory 
elements for NF-kB and AP-1 [89], making it likely that HBD-1 is constitutively pro­
duced and is not transcriptionally regulated by infammatory agents [72, 73, 90-93] 
but  could  also  be augmented by  infammatory  stimuli.  However,  expression of 
hBD1 could be induced and upregulated by LPS, heat-inactivated Pseudomonas 
and INFγ.
hBD2  was originally isolated in 1997 from psoriasic skin lesions [71]. The most 
prevalent expression of hBD2 is observed in the skin and the gastrointestinal and 
respiratory  tracts;  however,  substantial  amounts  of  this  defensin  are  present 
throughout the entire epithelia. In contrast to hBD1, the hBD-2 gene expression is 
inducible by various proinfammatory agents such as TNF-α, IL-1 β and Gram-neg­
ative bacteria and to a lesser extent by Gram-positive bacteria and yeasts [71, 76], 
thus it may represent the human equivalent of bovine TAP and LAP. Indeed the 5ʻ-
fanking region of hBD-2 has been demonstrated to contain consensus binding se­
quences for NF-kB [94]. Therefore, hBD2 can be considered as the first described 
human inducible defensin. This psoriatic-scale derived hBD2 shows preferential 
antimicrobial activity against Gram negative bacteria (E.Coli,  Pseudomonas) and 
less activity against  Candida Albicans  and only bacteriostatic activity against  St. 
Aureus. It is interesting to note that hBD2 ability to inhibit bacteria growth dimin­
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ishes when salt concentration is increased, suggesting that hBD2 will be unable to 
kill bacteria in serum or on the skin surface covered with evaporated sweat. hBD2 
immunoreactivity is localized to the uppermost layers of the epidermis and/or strat­
um corneum. On a subcellular level, hBD2 is stored in lamellar bodies of stimu­
lated KC of the spinous layer of the epidermis, suggesting that hBD2 is released 
with the lipid-like contents of lamellar bodies. Inter-individual and site-specific dif­
ferences in intensity of immunostaining were observed, and the pattern of peptide 
localization was seen to be rather focal, similar to psoriasin staining, suggesting 
that hBD2 is locally induced. Stimulators of hBD2 expression include IL-1a (++), 
IL-1b (++), TNFa, INFg, PMA, isoleucine, vitamin D3, LPS and some Gram negat­
ive bacteria.
hBD3 was nearly simultaneously purified from psoriasic scales. hBD3 is a broad 
spectrum antimicrobial peptide, active against Gram negative and Gram positive 
bacteria, fungi, including MRSA (multi resistant Staphilococcus Aureus) and VRE 
(vancomycin resistant  Enterococcus).  hBD3 mRNA is expressed throughout the 
epithelia  of  many  organs and  in  some non-epithelial  tissues.  Transcripts  were 
found  in  skin,  tonsils,  gingival  KC,  esophagus,  trachea,  placenta,  adult  heart, 
skeletal muscle and fetal thymus. Similar to hBD2, expression of hBD3 is induced 
in keratinocytes and the respiratory epithelium by TNFα (+), IL-1β, INFγ (++), vari­
ous bacteria and yeast. In contrast to hBD2, upregulation of hBD3 expression in 
keratinocytes was observed in the presence of TGFα and IGF1. hBD3 seems to 
be less widely expressed than other human β-defensins such as hBD1 and hBD2. 
Harder et al  investigated the tissue distribution of hBD3 mRNA expression from 
various body sites by real-time RT-PCR and found low or no HBD3 mRNA expres­
sion in most of the analyzed organs including the respiratory, gastrointestinal, and 
genitourinary  tracts  [84].  Despite  the  low  hBD3  expression  in  biopsies  from 
gastrointestinal tract, purified epithelial cells of normal small  and large intestine 
were found to express high level of HBD3 mRNA [95].
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CATHELICIDIN
Cathelicidins are linear alpha-helical peptides and represent another major group 
of mammalian AMPs [96, 97]. Cathelicidins have been found in nearly all investig­
ated mammals [98]; about 35 cathelicidin members have been identified in various 
mammalian species but in humans there is only one cathelicidin, called LL-37 (or 
hCAP18) [99].
Genetics and structure
The gene encoding LL-37 is localized to chromosome 3 and contains four exons
[100].  Cathelicidins are synthesized as pre-pro-peptides. Generally,  the cathelin 
pro-peptide must be removed from the C-terminal peptide to unleash the microbi­
cidal activity [101]. All cathelicidins (figure 11) contain an N-terminal putative signal 
peptide (pre-region), a conserved pro-region cathelin-like domain (hence the name 
cathelicidin), and a carboxy-terminal microbicidal domain.
Source and expression
Initially, LL-37 was isolated from myelocytes and metamyelocytes and localized 
into  specific  neutrophils  granules  [102].  Thereafter  LL-37 was  demonstrated  in 
very different cells and tissue types (table 7).
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Figure 11: Schematic structure of human 
cathelicidin. The promoter region of the 
gene contains putative binding sites for 
many transcription factors such as nuclear 
factor NF-kB, IL-6, acute-phase response 
factor, activator protein 4 and 
CCAAT/enhancer-binding protein (C/EBP). 
(From Bals and Wilson [101].
Table 7: cell and tissue types where LL-37 has been found (adapted from Ulrich et al. [103] )
Several reports of up- and down-regulation of LL-37 have been described (table 
8). Up-regulation seems to be more common than down-regulation, indicating that 
these AMPs assists the immune system in fighting disease.
Table 8: up- and down-regulation of cathelicidin (adapted from Ulrich et al. [103]
LL-37 is up-regulated in skin in response to cutaneous infection or injury and in cu­
taneous infammatory disorders, such as psoriasis. In contrast, low expression of 
LL-37 has been detected in patients with atopic  dermatitis.  This apparent  defi­
ciency of LL-37 could suggest an explanation for the increased susceptibility of pa­
tients with atopic dermatitis to skin infection, compared to patients with psoriasis, 
who are not more prone to skin infections than to healthy subjects.
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Functions and role in humans
Cathelicidins have different functions (figure 12), similar to the other members of
AMPs.
Figure 12: biological functions of cathelicidin antimicrobial peptides. Cathelicidins are secreted by­
several cell types during infection and infammation. Cathelicidins have direct antimicrobial activity 
and regulate cellular responses including cell proliferation, cell migration of infammatory cells, re­
lease of cytokines and angiogenesis. (From Bals R, Wilson JM. [ 101]
It has been demonstrated that LL-37 has specific functions and interacts with sev­
eral other infammatory molecules at very different concentrations (figure 13).
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Figure 13: concentrations of LL-37 required to different activities and functions.
Cathelicidin has a broad spectrum of antimicrobial activity against gram positive 
and gram negative bacteria, and even against yeasts. It is noteworthy that in pa­
tients with Kostmannʼs disease there is an absence of LL-37 in the granulocytes 
and  saliva  and,  unless  treated  with  G-CSF  (granulocytes  colony  stimulation 
factor), these patients usually die from bacterial infections within their first year of 
life [104]. This clearly highlights the role of cathelicidin in the regulation of the im­
mune system in fighting infectious diseases.
Cathelicidin has a chemotactic activity on several cells of the immune systems, i.e.
leukocytes [105], and increased levels of this AMP are regularly found in infamed 
or infected tissues. Mast cells are also under the infuence of LL-37: it has been 
demonstrated that LL-37 could induce degranulation [106] and migration [107] of 
mast cells.
Some recent studies have demonstrated increased levels of LL-37 in human skin 
after a wound had been inficted [108]. The role of AMPs in wound healing has 
also been studied for other AMPs.
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ELAFIN
Elafin was first isolated from sputum secretions of patients with chronic obstructive 
pulmonary disease and cystic fibrosis [109, 110]. This protein, together with the 
secretory-leukocytes-proteinase-inhibitor  (SLPI),  belongs to  the family  of  “alarm 
antiproteases”.
These anti-proteases have been classified as either “systemic” or “alarm” [111]. 
Alarm anti-proteases are synthesized and secreted by cells local to the site of in­
fammation in response to the release of infammatory cytokines (as IL-1) [112]. 
Therefore,  anti-proteases could be crucial  to  prevent  and contrast  tissue  injury 
from excessive release of proteolytic enzymes and infammatory molecules by in­
fammatory cells.
Genetics and structure
Characterization of elafin was complete 20 years after its discovery [113]. Elafin is 
composed of two regions (figure 14): a globular C-terminus WAP/four-disulphide 
core domains and a fexible NH2  domain referred to as ʻʻcementoin,ʼʼ or ʻʻtrappinʼʼ 
domain (hence one of the acronyms), which provides a substrate for the enzyme 
transglutaminase [115, 116]. This enzyme allows elafin to be cross-linked into poly­
mers or with extracellular matrix components [116].
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Figure 14: structure of elafin
Source and expression
Elafin is mainly produced by the body mucosae and by the skin. It was initially pur­
ified  from highly  infamed mucosal  secretions  where  neutrophils  recruitment  is 
prominent.
In the skin, elafin expression is constitutive in the squamous epithelium as a refec­
tion of its immuno-modularity properties [117]. It has been observed that in some 
infammatory diseases, as psoriasis, the expression of elafin is increased, correlat­
ing with the degree of neutrophils infux [118].
Functions and role in humans
It has been shown that elafin possesses a wide repertoire of activities, including 
antimicrobial [119-123] and immuno-modulator properties (figure 15).
The biochemical mechanisms of these properties have not been fully clarified but it 
has been speculated that the cationic nature of elafin allows it to disruptively inter­
act with the anionic cell membrane.
It has been found that there is an increase of anti-proteases levels in some dis­
eases where there is also an increase of protease activity, such as psoriasis and 
emphysema [125, 126]. Moreover, an increase in the level of these alarm anti-pro­
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Figure 15: antimicrobial and 
antiinfammatory functions of elafin
teases has also been found in diseases where no proteases activity is relevant, 
such as ischemic heart disease and lung cancer.
It has been recently demonstrated that the over-expression of elafin seems to pre­
vent intestinal infammation in the mouse model of colitis [127]. Furthermore, a  re­
cent study on humans has shown an increasing of elafin staining in infamed tissue 
of ulcerative colitis and Crohnʼs disease compared to healthy controls (figure 16). 
This study has also shown a higher expression of elafin in Crohnʼs disease com­
pared to Ulcerative Colitis. This observation, coupled with an imbalance between 
elastase and this antiprotease activity, could explain the more aggressive tissue 
destruction observed in Crohnʼs disease.
Figure 16: Representative immunohistochemical staining of elafin in controls (left), Crohnʼs dis­
ease (middle), and ulcerative colitis (right). From Schmid M et al. [128].
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PSORIASIN
Psoriasin (also known as S100A7) is a member of the S100 gene family and was 
first isolated in 1991 from keratinocytes of psoriatic epidermis [129].
Genetics and structure
The psoriasin  gene  is  located  to  chromosome 1q21.2-q22,  within  a  cluster  of 
genes that include at least 12 of the S100 gene family termed the “epidermal dif ­
ferentiation complex” (EDC) [130, 131].
Source and expression
In skin, psoriasin is focally expressed and released from keratinocytes, particularly 
in areas where high bacterial colonization is well documented, such as the upper­
most parts of hair follicles and nose skin. Dry areas of the skin, such as lower leg 
skin, show instead a rather “patchy” staining for psoriasin. It is interesting to note 
that,  apart from keratinocytes, sebocytes, the lipid-secreting cells of sebaceous 
glands, also show immuno-reactive psoriasin, suggesting that psoriasin is possibly 
also secreted together with lipids; probably, psoriasin is stored in the lipid layer of 
healthy skin [132].
Psoriasin has been found in other different tissues and organs beside skin, such 
as  tongue,  ear  and  eye.  Recently  it  has  been  demonstrated  that  psoriasin  is 
secreted by neoplastic keratinocytes in bladder carcinoma, in neoplastic breast 
ductal epithelium and in bronchial epithelium of patients affected by cystic fibrosis. 
Interestingly, it has been found that psoriasin protects the embryo from infections, 
since this molecule was found both in the vernix caseosa and in amniotic fuid 
[133].
Functions and role in humans
The skin is in direct contact with the environment and produces different AMPs 
with a broad spectrum of activity against several bacteria. Glaser et al [136] have 
demonstrated that, although different bacterial strains survive on fingertips [137], 
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E.Coli  is rapidly killed. These authors have identified psoriasin (S100A7) as the 
principal E.Coli-killing AMP and the expression of this protein on the skin could ex­
plain why skin regions after exposed to high concentrations of E.Coli (as anogenit­
al skin) are not usually infected from these bacteria.
Moreover, this observation could explain why patients with psoriasis, an infammat­
ory skin disease characterized by infammatory lesions and hyper-proliferation of 
epidermis, could suffer from skin infections but rarely from E.Coli [138].
Patients with atopic dermatitis frequently have Staphylococcus Aureus super-infec­
tions and colonization of the skin, but not from E.Coli. The same group of authors 
have demonstrated that, although a deficiency of some AMPs is detectable, there 
is  an enhanced epidermal  psoriasin  expression in  atopic  dermatitis  [140].  This 
could indicate that the antimicrobial response in this skin disease is not generally 
impaired, but greatly differs according to the type of AMP produced by the skin.
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RATIONALE AND
AIM OF THE STUDY
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Rationale of the study
The possible link between eosinophilic  esophagitis (EoE) and other  atopic  dis­
eases has already been investigated and extensively reviewed by Jyonouchi et al 
[141]. In particular, this link seems to be stronger between asthma/atopic dermatit­
is (AD) and EoE. In those diseases the remodeling of the involved tissues (base­
ment membrane in the lung, basal layer of esophagus and epithelial layer in the 
skin) is due to the deposition of collagen with consequent fibrosis [142-144]. The 
Th2-skewed environment enhances the production and activation of eosinophils, 
creating favorable conditions to the development of atopy. In addition, the homing 
signals for Th2 cells and eosinophils are increased both in EoE and atopic dis­
eases  [30,  145-148].  These findings suggest  that  EoE,  even when no allergic 
sensitization is proven, belongs to the Th2-driven diseases.
In particular,  EoE shares some clinical and histological characteristics with AD, 
such as the macroscopic (i.e. they both are a “patchy” disease) and microscopic 
appareance (i.e. both of them are characterized by eosinophilic infiltration),  the 
good  response  to  topical  steroids  treatment  and  allergen  avoidance,  the  diffi­
cult-to-find allergic causative sensitization.
Regarding  etiopathogenesis,  a  hypothetical  common mechanism between  EoE 
and AD could be a dysregulation of the innate immune system. Several Authors 
have demonstrated a genetically determined epithelial barrier dysfunction in AD 
due to abnormalities in filaggrin function [149-151], while other studies have sug­
gested that an alteration of epithelial barrier functions could be the basis for the
development of atopic sensitization, atopic dermatitis and, possibly, asthma in pa­
tients with eczema [152]. In line with this observation, filaggrin mutations seem to 
have a role in the pathogenesis of asthma [153] and filaggrin expression seems to 
be down-regulated also in EoE, as recently demonstrated [154], although a previ­
ous study [155] failed to stain filaggrin in normal esophageal biopsies.
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Another crucial component of the innate immune system is constituted by antimi­
crobial peptides and proteins (AMPs). In lesional AD skin it has been shown that 
some AMPs, such as cathelicidin and the β-defensins, may show defective func­
tions [156, 157] and their expression is significantly reduced if compared to  psori­
asis,  another chronic skin disease [158].
To underscore the importance of our investigation, while we were conducting this 
study, a study group from Colorado [159] has addressed the same hypothesis, al­
though testing a more restricted panel of AMPs on a population that included only 
active EoE patients and controls.
These observations could re-enforce the possible link between EoE and AD.
Aim of the study
In this study we wanted to investigate the presence and expression levels of selec­
ted AMPs in esophageal biopsies (hBD-1, hBD-2, cathelicidin, elafin, and psorias­
in) of children with active EoE (5 children), with EoE in remission (5 children) and 
in healthy controls (5 children).
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METHODS
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Patients and tissue selection
A total of 15 children (age range 0-18 years), undergoing EGD between January 
2008 and January 2011, were studied.
Children were randomly and anonymously selected from a larger cohort of chil­
dren, referred to the Childrenʼs Hospital  of Philadelphia to undergo esophageal 
biopsies. These children were prior to the randomization divided into three groups 
prior to the randomization:
- children with positive esophageal biopsies (more than 20 eosinophils/hpf) and a 
clinical history compatible with EoE (“active” group);
- children with negative esophageal biopsies and a clinical history compatible with 
EoE (“not active” group);
-  children with negative esophageal  biopsies and no clinical  history compatible 
with EoE (“negative” group).
From each group, 5 children were randomly selected. Biopsies were marked only 
with the archiveʼs number and retrieved from Pathology Core archive.
The study was approved by the local ethical committee and a written consensus 
was signed by the parents and by the child (if older than 7 years old).
Immunohistochemistry (IHC)
Due to  the  limited number  of  slides obtained by the  paraffinated biopsies,  we 
chose to stain the slides with the most known hBD1, elafin and psoriasin. IHC for 
elafin, psoriasin and hBD1 was performed as follows (from [160]):
- deparaffinated and alcohol-fixed tissue sections from esophageal biopsies of chil­
dren who underwent EGD were boiled for 30 minutes in buffered saline (pH 6.0), 
for antigen retrieval;
- after blocking of endogenous peroxidase, slides were incubated overnight with 
the  primary  antibody  directed against  elafin  (Santa  Cruz  Biotechnology,  Santa 
Cruz, California, USA; sc-20637, diluted 1 : 200), psoriasin (Biocarta, San Diego, 
California,  USA, diluted 1 :  200) and hBD1 (AlphaDiagnostic International,  San 
Antonio, Texas, USA, diluted 1 : 1.000);
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- immunostaining was visualized using a detection kit as outlined by the supplier 
(Dako;  K-5007,  horseradish  peroxidase-labeled  secondary  antibody,  detection 
with 3ʼ-diaminobenzidine tetrahydrochloride); 
- sections were counterstained with hematoxylin.
Evaluation of immunostaining
To quantify AMPs expression we performed an image analysis study employing 
Image J software (NIH;  http://rsbweb.nih.gov/ij/). Briefy, digital images were ac­
quired with a dedicated microscope set-up (Leica DMD 180),  RGB (red-green-
blue) channels were split, blue channel (the one containing the largest information 
on immunostaining positivity) was thresholded and positive pixels were quantified. 
The  green  channel  was  employed  to  threshold  the  whole  image  section.  The 
volume fraction occupied by the positive signal was quantified as a ratio between 
positive area/total area.
Real Time quantitative PCR
RNA preparation and reverse transcription
Frozen biopsies were disrupted mechanically in 1 mL of Trizol (Gibco BRL, Eggen­
stein, Germany) with an Ultra-Turrax (Branson, Danbury, Connecticut, USA)until 
complete fragmentation. Total RNA was extracted according to the supplierʼs pro­
tocol.  RNA quality was determined by electrophoresis and quantified by photo­
metry. Subsequently, 2 μg RNA was reverse transcribed with oligo dT-primers and 
200U reverse transcriptase (RT) (Superscript; Gibco BRL),  according to routine 
procedure.
Real-time PCR analysis
Real-time  PCR  analyses  were  performed  using  single-stranded  cDNA  from 
biopsies with specific oligonucleotide primer pairs in a thermocycler equipped with 
a fuorescence detection monitor (SD-7000, Applied Biosystem).
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1 uL cDNA (corresponding to 10 ng of RNA) served as a template in a 20 uL reac­
tion containing 10 uL of Power SYBR Green Master Mix (Roche Diagnostic), 0.5 
uL of each primer (forward and reverse, 10 uM stock, ready to use) and 8 uL of  
RNA free water. All amplifications were carried out in triplicate. The temperature 
profile was 95°C for 10 seconds, 62°C for 5 seconds and 72°C for 2 seconds.
Primers sequences and amplicon size
From: Hosakaa Y et al. [160]
RT-qPCR data analysis
Analysis of relative gene expression data was carried out by employing the 2-ΔΔCt
method, as previously described [161].
Statistics
All statistical analyses and graphs were carried out using Prism 4.0 software (La 
Jolla,  California,  USA). For comparison of nonparametric quantitative RT-qPCR 
data we used the Kruskall-Wallis test. To compare differences among groups of 
IHC data we employed One-Way ANOVA followed by Bonferroni post-hoc test. Val­
ues of P<0.05 were considered statistically significant.
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RESULTS
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hBD1
Real-Time quantitative PCR
In order to verify whether the expression of hBD1 was dysregulated in patients 
with active and not active EoE, we performed a Real-Time quantitative PCR (RT-
qPCR) experiment comparing EoE patients with healthy controls.
As shown in figure 1, when we compared the relative amount of hBD1 normalized 
to the internal reference (GAPDH) and relative to a calibrator (healthy controls) 
with the 2-ΔΔCt method, we observed that patients with active EoE showed a trend 
toward increased expression of this gene with respect to both not active EoE and 
healthy controls. Furthermore not active EoE patients showed a trend toward a re­
duced expression compared to healthy controls. However, no statistically signific­
ant difference was observed. Moreover, the relative amount of target gene quanti­
fied by the 2-ΔΔCt method showed that active EoE patients had 1.87 ± 3.56 fold the 
hBD1 expressed by healthy controls, and not active EoE patients had 0.54 ± 0.54 
fold the hBD1 expressed by healthy controls.
Figure 1: hBD1 expression evaluated by RT-qPCR; histograms
represent mean and error bars indicate standard deviation
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Immunohistochemistry (IHC)
Moving from the consideration that RT-qPCR data were suggestive but non con­
clusive of differential expression of the tested gene between active/not active EoE 
and healthy controls, we decided to quantify the protein expression by IHC and 
morphometry. As shown in figure 2, hBD1 could be detected in all cases; however, 
differences in protein expression between the three groups could be observed. To 
quantify  these  differences,  a  morphometric  analysis  was  performed  and  the 
volume fraction occupied by the cells positive to this protein was computed. Figure 
3 summarizes the results obtained from the statistical analysis. Interestingly, active 
EoE patients showed a statistically significant increased expression compared to 
not active EoE patients.
Figure 2: hBD1 expression in esophageal biopsies of active EoE, not active EoE and healthy con­
trols.
Altogether these results indicate that EoE patients are characterized by altered ex­
pression of hBD1.
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Figure 3: hBD1 expression 
evaluated by IHC; histograms 
represent mean and error bars 
indicate standard deviation.
p<0.05 versus active EoE 
patients.
hBD2
Real-Time quantitative PCR
In order to verify whether the expression of hBD2 was altered in patients with act­
ive and not active EoE, we performed a RT-qPCR experiment, comparing EoE pa­
tients with healthy controls.
As shown in figure 4, when we compared the relative amount of hBD2 normalized 
to the internal reference (GAPDH) and relative to a calibrator (healthy controls) 
with the 2-ΔΔCt method, we observed that patients with active EoE showed a trend 
toward reduced expression of this gene with respect to both non active EoE and 
healthy controls.  However this  difference failed to reach statistical  significance. 
Quantitatively, the relative amount of target gene quantified by the 2-ΔΔCt  method 
showed that active EoE patients had 0.15 ± 0.14 fold the hBD2 expressed by 
healthy controls, and non active EoE patients had 0.22 ± 0.14 fold the hBD2 ex­
pressed by healthy controls.
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Figure 4: hBD2 expression 
evaluated by RT-qPCR ; 
histograms represent mean and 
error bars indicate standard 
deviation.
Cathelicidin (LL-37)
Real-Time quantitative PCR
In order to verify whether the expression of cathelicidin was dysregulated in pa­
tients with active and non active EoE, we performed a RTqPCR experiment, com­
paring EoE patients with healthy controls.
As shown in figure 5, when we compared the relative amount of cathelicidin nor­
malized to the internal  reference (GAPDH) and relative to a calibrator (healthy 
controls) with the 2-ΔΔCt method, we observed that neither patients with active EoE 
nor those with not active EoE showed levels of cathelicidin different from healthy 
controls.
Quantitatively, the relative amount of target gene quantified by the 2-ΔΔCt  method 
showed that active EoE patients had 1.19 ± 1.12 fold the cathelicidin expressed by 
healthy controls, and not active EoE patients had 1.32 ± 1.45 fold the cathelicidin 
expressed by healthy controls.
Figure 5: cathelicidin expression evaluated by RT-qPCR; histograms
represent average and error bars indicate standard deviation.
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Elafin
Real-Time quantitative PCR
In order to verify whether the expression of elafin was dysregulated in patients with
active and not active EoE, we performed a RT-qPCR experiment, comparing EoE 
patients with healthy controls.
As shown in figure 6, when we compared the relative amount of elafin normalized 
to the internal reference (GAPDH) and relative to a calibrator (healthy controls) 
with the 2-ΔΔCt method, we observed that patients with EoE showed a trend toward 
reduced expression of this gene with respect to healthy controls. However this dif­
ference failed to reach statistical significance.
The amount of target gene quantified by the 2-ΔΔCt method showed that active EoE 
patients had 0.41± 0.38 fold the elafin expressed by healthy controls, and not act­
ive EoE patients had 0.52 ± 0.42 fold the elafin expressed by healthy controls.
Figure 6: elafin expression evaluated by RT-qPCR; histograms
represent average and error bars indicate standard deviation.
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Immunohistochemistry
Moving from the consideration that RT-qPCR data were suggestive but non con­
clusive of differential expression of the tested gene between active/not active EoE 
and healthy controls, we decided to quantify the protein expression by IHC and 
morphometry. As shown in figure 7, elafin was detected in all cases; in addition,  
differences in protein expression between the three groups could be observed. To 
quantify  these  differences,  a  morphometric  analysis  was  performed  and  the 
volume fraction occupied by the cells positive to this protein was computed. Figure 
8 and Figure 9 summarize the results obtained from the statistical analysis. Al­
though active EoE and not active EoE patients, taken as separate groups, failed to 
reach a statistically significant difference, the combined group of children suffering 
from EoE showed, irrespectively from the active or not active status of the disease, 
a statistically significant decreased expression of Elafin, compared to healthy con­
trols.
Figure 7: Elafin expression in esophageal biopsies of active EoE, not active EoE and healthy con­
trols.
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Figure 8: Elafin expression 
evaluated by IHC; histograms 
represent mean and error bars 
indicate standard deviation.
Altogether these results indicate that the expression of Elafin is significantly re­
duced in EoE patients, irrespectively of the disease activity, strongly suggesting a 
constitutive down-regulation of this protein.
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Figure 9: Elafin expression 
evaluated by IHC; histograms 
represent mean and error bars 
indicate standard deviation.
p<0.05 versus active+not active 
EoE patients.
Psoriasin
Real-Time quantitative PCR
In order to verify an abnormal expression of psoriasin in patients with active and 
not active EoE, we performed a RT-qPCR experiment, comparing EoE patients 
with healthy controls.
As shown in figure 10, when we compared the relative amount of psoriasin nor­
malized to the internal  reference (GAPDH) and relative to a calibrator (healthy 
controls) with the 2-ΔΔCt method, we observed that patients with active EoE showed 
a trend toward increased expression of this gene with respect to both not active 
EoE and healthy controls even that this difference is not statistically significant. 
The not  active EoE patients showed a similar expression compared to healthy 
controls. The amount of target gene quantified by the 2-ΔΔCt  method showed that 
active EoE patients had 1.87 ± 2.14 fold the psoriasin expressed by healthy con­
trols, and not active EoE patients had 1.45 ± 2.16 fold the psoriasin expressed by 
healthy controls.
Immunohistochemistry
Moving from the consideration that RT-qPCR data were suggestive but not con­
clusive of differential expression of the tested gene between active/not active EoE 
and healthy controls, we decided to quantify the protein expression by IHC and 
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Figure 10: psoriasin expression
evaluated by RT-qPCR; histograms 
represent average and error bars 
indicate standard
deviation.
morphometry. As shown in figure 11, psoriasin was detected in all cases; and in all 
times, differences in protein expression between the three groups could be ob­
served. To quantify these differences, a morphometric analysis was performed and 
the volume fraction occupied by the cells positive to this protein was computed. 
Figure 12 and Figure 13 summarize the results obtained from the statistical ana­
lysis. Interestingly, both active EoE and not active EoE patients showed a statistic­
ally significant difference compared to healthy controls.
Figure 11: Psoriasin expression in esophageal biopsies of active EoE, not active EoE and healthy
controls.
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Figure 12: Psoriasin expression
evaluated by IHC; histograms 
represent mean and error bars 
indicate standard deviation.
* p<0.05 versus active.
**p<0.05 versus not active EoE 
patients.
Altogether these results indicate that the expression of psoriasin is reduced in EoE
patients, independently of the disease status, suggesting a constitutive downregu­
lation of this protein.
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Figure 13: Psoriasin expression
evaluated by IHC; histograms 
represent mean and error bars 
indicate standard deviation.
* p<0.05 versus active+not active 
EoE.
Summary of the principal findings
Table 1 summarizes the principal findings of RealTime qPCR and immunohisto­
chemistry analysis. It is apparent at a glance that there is an alteration of all tested 
AMPs.
AMP RealTime qPCR IHC
Active EoE Not Active 
EoE
Active EoE Not Active 
EoE
Active + Not 
Active EoE
hBD1 ⬆ vs control
(1.87 ± 3.56)
⬇ vs control
(0.54 ± 0.54)
⬇vs active ✵ N/A
hBD2 ⬇ vs control
(0.15 ± 0.14)
⬇ vs control
(0.22 ± 0.14)
N/A N/A N/A
Cathelici­
din
 =vs control
(1.19 ± 1.12)
 =vs control
(1.32 ± 1.45)
N/A N/A N/A
Elafin ⬇ vs control
(0.41± 0.38)
⬇ vs control
(0.52 ± 0.42)
⬇ vs control ⬇ vs control ⬇vs control ✵
Psoriasin  =vs control
(1.87 ± 2.14)
 =vs control
(1.45 ± 2.16)
⬇vs control ✵ ⬇vs control ✵ ⬇vs control ✵
Table 1: summary of presented data. Red boxes indicate upregulation, green boxes indicate down­
regulation. Numbers between parenthesis indicate fold expression.  ✵  indicate statistically signifi­
cant data, p<0.05. N/A not assessed
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DISCUSSION
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The present work deals with a clinically relevant and original issue to deepen our
knowledge on the pathophysiology of EoE and to improve both the diagnostic and
therapeutic options for patients affected by this chronic invalidating disease.
This study was based on the consideration that EoE seems to share some clinical
characteristics with AD. These two diseases, although localized to different dis­
tricts with distinct embryological origins, have a similar macroscopic appearance, 
both being a “patchy” disease characterized by eosinophilic infiltration, and show a 
good clinical and histological response to topical steroid treatment and widened al­
lergensʼ avoidance. Regarding etiology, both diseases are characterized by a diffi­
culty in finding a specific allergic causative sensitization. Indeed EoE is, at least 
partially, a Th2-driven disease and a pathogenetic role for Th2-cytokines, as IL-5 
and IL-13, has been observed in EoE models [6, 21, 162, 163]. In AD a Th1/Th2 
imbalance has also been demonstrated [164], and a defect in innate immunity has 
been detected [165].  The possible link between EoE, AD and other atopic dis­
eases has been recently addressed by Brown-Whitehorn and Spergel [28]. In this 
review it is discussed how EoE shares clinical and histological characteristics with 
other atopic diseases, as AD, asthma, allergic rhinitis. However, a clear relation­
ship between EoE and AD has yet to be proven.
The etiopathogenesis of EoE is an open research field and different studies have 
tried to analyze the role of defects in both innate and adaptive immune systems. 
Beside in well-known immunodeficiencies, alterations of the innate immune sys­
tem have been found in other human diseases, such as in infammatory bowel dis­
eases [95, 127] and in atopic dermatitis [165]. It has been suggested that a defect 
in  innate  immunity  and,  specifically,  in  some AMPs could  contribute  to  the  in­
creased susceptibility of patients with AD for viral skin infections, as eczema her­
peticum [166], although controversies are still open in this regard [167].
However, it seems to be clear that a dysregulation of AMPs is present in AD (figure
1).
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Figure 1: Immunopathogenesis of AD. (from Wollenberg et al. [156])
Therefore, we tested the hypothesis that, in analogy with AD, EoE patients could 
have a dysregulation of AMPs, too. For this purpose, a total of fifteen children were
enrolled in this study; of these, five were affected by EoE (histology-proven) in act­
ive state, five were in remission state and five healthy children were tested as con­
trols. We decided to test not only active EoE, but not active EoE patients too, since 
EoE is a progressive chronic disease, even when in a remission state. In this way, 
we aimed to evaluate whether there was an alteration of AMPs depending not only 
on active lesions but also on chronic infammation, since AMPs comprise proteins 
and peptides whose expression is both constitutive and inducible by infammatory 
cytokines and stimuli.
In our study population, we evaluated the expression of hBD1, hBD2, cathelicidin,
elafin and psoriasin genes by RT-qPCR, observing an altered expression in the 
tested AMPs. Specifically, we documented a reduced expression of hBD2, catheli­
cidin and elafin in EoE patients (both active and not active) compared to controls; 
regarding hBD1, we found a slight increased expression in active EoE compared 
to controls (not statistically significant) and a reduced expression in not active EoE 
compared to controls. Last, we documented a slight increased expression of psori­
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asin in active EoE with respect to controls, while not active EoE showed almost 
equal expression levels compared to controls. However, all these results failed to 
reach statistical significance.
Although RTqPCR is nearly the most sensitive and accurate method for gene ex­
pression quantification, these findings do not necessarily correspond to protein ex­
pression levels. Therefore, in order to verify whether these trends resulted in a 
similar altered expression of AMPs proteins, we analyzed the esophageal biopsies 
by IHC. We were able to confirm RT-qPCR data for hBD1 and elafin, while psori­
asin showed reduced expression levels both in active and not active EoE patients 
compared to controls. 
The possibility to recruit both EoE patients with active and not active disease gave 
us the opportunity to verify the behavior of inducible AMPs in response to infam­
mation. In this regard, the behavior of elafin and psoriasin is paradigmatic, since 
both active and not active EoE patients showed protein levels below controls. Im­
portantly, a reduced induction of elafin [128] and psoriasin [168] has also been de­
scribed in patients suffering from Crohnʼs disease (CD). Although this is not an 
atopic disease, CD is characterized by infammation and dysregulation of AMPs. 
The importance of the topic addressed by this thesis is testified by the fact that, 
while we were in the process of conducting the analysis, a study group in Colorado 
(from the Section of  Pediatric  Gastroenterology Hepatology and Nutrition,  Chil­
drenʼs Hospital Colorado, CO) has reported in an international conference results 
that are in line with our observation. In particular, they observed a statistically sig­
nificant reduced expression of hBD1-2-3 in EoE patients compared to healthy con­
trols [159]. With respect to this latter study, however, the work of this thesis has 
broadened the observation to other AMPs (cathelicidin, elafin and psoriasin) and 
has added the information on non active EoE patients.
Limits of the study
This is an exploratory study whose aim was to investigate possible alterations of 
AMPs in EoE. For this reason the study population was limited thus reducing the 
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statistical power, especially for RT-qPCR analysis. Nonetheless, we were able to 
find important and novel statistically significant alterations that suggest that this 
phenomenon deserves further investigations on a wider cohort.
In addition, our study has shown an association between EoE and AMP alterations 
but it did not investigate whether these latter have a causative role in the etiopath­
ogenesis of this disease. To address this issue, experimental studies both in vitro 
and in vivo are advocated.
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